Nicholas Hornstein, Assistant Professor at Northwell Health, shared a post on LinkedIn:
“Say it with me: no patient should ever start at 160 mg of regorafenib.
New real-world data from ASCO GI 2026 (Abstract 136) back up what many of us already do in clinic.
Italian mCRC cohort comparing three strategies:
- ReDOS step-up dosing
- Fixed reduced dosing (<160 mg)
- Standard upfront dosing (160 mg)
Overall survival favored ReDOS and fixed reduced dosing over full-dose initiation (7.4 vs 8.3 vs 6.1 months). No survival advantage to starting at 160 mg.
Progression-free survival also favored ReDOS versus both comparators.
No excuses anymore, follow ReDOS and improve toxicity without sacrificing efficacy.”
More posts featuring Nicholas Hornstein.